Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)
- 13 June 2009
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (15), 4050-4054
- https://doi.org/10.1016/j.bmcl.2009.06.016
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of CancerJournal of Medicinal Chemistry, 2008
- Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancerBioorganic & Medicinal Chemistry, 2008
- ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsClinical Cancer Research, 2007
- Poly(ADP-ribose) Polymerase as a Drug Target for Cardiovascular Disease and Cancer: An UpdateDrug News & Perspectives, 2007
- Inhibition of poly(ADP-ribose) polymerase in cancerCurrent Opinion in Pharmacology, 2006
- Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymeraseBioorganic & Medicinal Chemistry Letters, 2006
- Chemopotentiation by PARP inhibitors in cancer therapyPharmacological Research, 2005
- New inhibitors of poly(ADP-ribose) polymerase (PARP)Expert Opinion on Therapeutic Patents, 2004
- The Therapeutic Potential of Poly(ADP-Ribose) Polymerase InhibitorsPharmacological Reviews, 2002
- The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapyBiochimie, 1995